Loading…
Based on limited metadata with no full letter text available, the FDA issued a Warning Letter to American Chinese Medicine Association on June 26, 2018, regarding products categorized as "Other" (not a standard drug, device, or supplement category). Without access to the subject line or detailed violation information, the specific regulatory concerns cannot be determined from the available metadata alone. The issuing office is also unknown, which limits clarity on whether violations involved manufacturing, marketing, labeling, or other compliance areas. Additional documentation would be needed to identify the precise nature of FDA's enforcement action.